Bioavailability Enhancement Technologies and Services Market by Type of Drug Class

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: OVERVIEW

As per Roots Analysis, the global bioavailability enhancement technologies and services market is estimated to grow from USD 3.2 billion in the current year to USD 10.22 billion by 2035, at a CAGR of 11.11% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Drug Class

New Drug Approvals

Generics

Type of BCS Classification

BCS II Drugs

BCS IV Drugs

Type of Bioavailability Enhancement Approach

Solid Dispersion

Size Reduction

Lipid-based

Other Approaches

Type of Dosage Form

Liquids

Solids

Semi-Solids

Fine Particles

Key Geographical Regions

North America

Europe

Asia

Latin America

Middle East and North Africa

Rest of the World

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: GROWTH AND TRENDS

In recent years, the focus of drug developers has shifted towards development of lipophilic drug compounds due to the increasing issues with aqueous solubility of drugs. According to a recent study, around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability, the demand for novel bioavailability enhancement methods has grown significantly.

It is worth mentioning that since 2000, more than 55 players offering bioavailability enhancement technologies and services have been established. Amidst the growing competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor. This has led many service / technology providers to actively expand their portfolios, either through strategic acquisitions / mergers or entering into service alliances with other bioavailability enhancement companies. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace over the next decade.

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY INSIGHTS

The report delves into the current state of the bioavailability enhancement technologies and services market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles.

At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach.

Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers.

Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route.

A rise in partnerships focused on bioavailability enhancement services and technology platforms validates the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions.

In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions.

5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby indicating the rapid pace of research activity within this domain.

Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio.

With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition.

Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future.

Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035.

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY SEGMENTS

New Drug Approvals Occupy the Largest Share of the Bioavailability Enhancement Technologies and Services Market

Based on the type of drug class, the market is segmented into new drug approvals and generics. At present, new drug approvals hold the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the near future.

BCS II Drug Class is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of BCS classification, the market is segmented into BCS II drugs and BCS IV drugs. Currently, BCS II drug class holds the maximum share of the bioavailability enhancement technologies and services market. This trend is likely to remain the same in the coming decade.

Size Reduction Approach is the Fastest Growing Segment of the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of bioavailability enhancement approach, the market is segmented into solid dispersion, size reduction, lipid-based and other approaches. It is worth highlighting that, lipid-based approach holds a larger share of the bioavailability enhancement technologies and services market. However, the bioavailability enhancement technologies and services market for size reduction approach is likely to grow at a relatively higher CAGR.

Liquid Dosage Form is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market

Based on the type of dosage form, the market is segmented into liquids, solids, semi-solids and fine particles dosage form. Currently, liquid dosage form holds the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the foreseeable future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia is expected to grow at a higher CAGR.

Example Players in the Bioavailability Enhancement Technologies and Services Market

Adare Pharma Solutions

Ascendia Pharmaceuticals

Catalent

Lonza

Lubrizol Life Science Health

Pace Life Sciences

Quotient Sciences

WuXi STA

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bioavailability enhancement technologies and services market, focusing on key market segments, including [A] type of drug class, [B] type of BCS classification, [C] type of bioavailability enhancement approach, [D] type of dosage form, and [J] key geographical regions.

Market Landscape 1: A comprehensive evaluation of bioavailability enhancement service providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, [F] type of dosage form supported, and [G] route of administration of drug product.

Market Landscape 2: A comprehensive evaluation of bioavailability enhancement technology providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of employee count), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, [F] type of molecule, [G] type of dosage form supported, [H] route of administration, [I] availability for license and [J] associated intellectual property rights.

Key Insights: A detailed analysis, encompassing the contemporary market trends, using six schematic representations, including [A] a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, [B] a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, [C] a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, [D] a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, [E] an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered), as well as [F] a 3D bubble analysis comparing the key players engaged in drug bioavailability enhancement market, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).

Company Profiles: In-depth profiles of key industry players offering bioavailability enhancement technologies and services, focusing on [A] company overviews, [B] financial information (if available), [C] bioavailability enhancement services portfolio, [D] recent developments and [E] an informed future outlook.

Competitive Benchmarking Analysis: A competitive benchmarking analysis that emphasizes the primary focus areas of various players engaged in the drug bioavailability enhancement market. This analysis compares their existing capabilities within and beyond their respective peer groups based in North America, Europe, Asia-Pacific, and other regions. It offers stakeholders insights into potential strategies for achieving a competitive edge in the industry.

Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.

Publication Analysis: A detailed review of peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as [A] year of publication, [B] type of publication, [C] popular keywords, [D] top journals, [E] top publishers and [F] top copyright holders (in terms of number of articles published).

Patent Analysis: Detailed analysis of various patents filed / granted related to bioavailability enhancement approaches and technologies based on [A] type of patent, [B] patent application year, [C] patent publication year, [D] bioavailability enhancement approach, [E] CPC symbols, [F] geography, [G] emerging focus area, [H] type of organization, [I] leading industry and non-industry players (in terms of number of patents filed/granted), and [J] individual patent assignees (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various bioavailability enhancement of various drug compounds and / or candidates based on parameters like [A] trial registration year, [B] trial phase, [C] current recruitment status, [D] enrolled patient population, [E] study design, [F] type of sponsor / collaborator, [G] leading industry and non-industry players (in terms of number of registered trials conducted), [H] type of molecule and [I] key geographies.

Technology Evaluation Framework: An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

What are the factors that are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

Free Updated report if the report is 6-12 months old or older